Characteristics | Non-high FeNO and non-high blood eosinophils (n = 53) | High FeNO and high blood eosinophils (n = 53) | p-value |
---|---|---|---|
Sex | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 1.0000 |
 Male | 48.4 (16.7) | 48.2 (16.9) |  |
Age | |||
 n (% non-missing) | 53.0 (100.0) | 53.0 (100.0) | 0.9647 |
 Mean (SD) | 48.4 (16.7) | 48.2 (16.9) |  |
 Median (IQR) | 53.0 (32.0) | 53.0 (31.0) |  |
Age group | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.8655 |
 Under 35 | 14 (26.4) | 14 (26.4) |  |
 35–65 | 31 (58.5) | 29 (54.7) |  |
 66–80 | 8 (15.1) | 10 (18.9) |  |
Smoking status | |||
 n (% non-missing) | 46 (86.8) | 46 (86.8) | 1.0000 |
 Non-smoker | 31 (58.5) | 31 (58.5) |  |
 Ex-smoker | 4 (7.5) | 4 (7.5) |  |
 Current smoker | 11 (20.8) | 11 (20.8) |  |
BMI | |||
 n (% non-missing) | 52 (98.1) | 51 (96.2) | 0.0386 |
 Mean (SD) | 29.0 (5.9) | 26.8 (5.6) |  |
 Median (IQR) | 28.4 (8.3) | 25.6 (7.1) |  |
FeNO | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | < 0.0001 |
 Mean (SD) | 18.6 (7.7) | 57.8 (26.4) |  |
 Median (IQR) | 20.0 (10.0) | 49.0 (28.0) |  |
Blood eosinophil count | |||
 n (% non-missing) | 53 (100.0) | 52 (98.1) | < 0.0001 |
 Mean (SD) | 0.1 (0.1) | 0.5 (0.3) |  |
 Median (IQR) | 0.1 (0.1) | 0.5 (0.2) |  |
Active eczema diagnosisa | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 1.0000 |
 Yes | 2 (3.8) | 2 (3.8) |  |
Active rhinitis diagnosisa | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.4052 |
 Yes | 15 (28.3) | 19 (35.8) |  |
Eczema diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.5355 |
 Yes | 16 (30.2) | 19 (35.8) |  |
Rhinitis diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.0451 |
 Yes | 15 (28.3) | 25 (47.2) |  |
IHD diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.5581 |
 Yes | 1 (1.9) | 2 (3.8) |  |
Heart failure diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) |  |
 Yes | 0 (0.0) | 0 (0.0) |  |
Hypertension diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.0990 |
 Yes | 15 (28.3) | 8 (15.1) |  |
Diabetes diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 1.0000 |
 Yes | 3 (5.7) | 3 (5.7) |  |
GERD active diagnosis | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.5063 |
 Yes | 6 (11.3) | 4 (7.5) |  |
Predicted peak flow | |||
 n (% non-missing) | 35 (66.0) | 39 (73.6) | 0.8838 |
 Mean (SD) | 513.0 (66.7) | 510.3 (69.9) |  |
 Median (IQR) | 487.5 (122.0) | 481.2 (128.0) |  |
ICS/LABA prescriptions per patient | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.2204 |
 Mean (SD) | 3.3 (3.9) | 4.0 (4.0) |  |
 Median (IQR) | 2.0 (5.0) | 3.0 (5.0) |  |
Mono ICS prescriptions per patient | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.1944 |
 Mean (SD) | 1.3 (2.3) | 0.8 (1.7) |  |
 Median (IQR) | 0.0 (1.0) | 0.0 (1.0) |  |
Mean daily SABA dosage (µg) | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.6923 |
 < 100 | 15 (28.3) | 16 (30.2) |  |
 100–200 | 19 (35.8) | 14 (26.4) |  |
 201–400 | 10 (18.9) | 14 (26.4) |  |
 > 400 | 9 (17.0) | 9 (17.0) |  |
ICS adherenceb | |||
 n (% non-missing) | 53 (100.0) | 53 (100.0) | 0.8149 |
 Mean (SD) | 64.1 (45.3) | 68.6 (72.5) |  |
 Median (IQR) | 54.8 (54.8) | 49.3 (49.3) |  |